Volume 11, Number 8, August 2005

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use

Conan MacDougall,* Spencer E. Harpe,* J. Patrick Powell,* Christopher K. Johnson,† Michael B. Edmond,* and Ron E. Polk*
*Virginia Commonwealth University, Richmond, Virginia, USA; and †Idaho State University, Boise, Idaho, USA

Figure 1. Fluoroquinolone use and resistance over study period. FQ, fluoroquinolone; Levo, levofloxacin; Cipro, ciprofloxacin; Moxi, moxifloxacin; Gati, gatifloxacin; DDD/1,000PD, defined daily doses/1,000 patient-days; FQ-R PSA, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed July 15, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention